Opus Genetics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8 Davis Dr Ste 220, Durham, North Caroli...Phone Number
(984) 884-6030Website
www.opusgtx.comRevenue
$14.2 MillionStock Symbol
IRDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company in the biotechnology and ophthalmology industry, focused on developing innovative gene therapies for inherited retinal diseases and other retinal and refractive disorders. Headquartered in the United States, the company conducts research and development in ophthalmic gene therapies and is dedicated to creating treatments that correct or compensate for genetic defects causing retinal degeneration. Opus Genetics aims to deliver durable, vision-preserving and vision-restoring therapies, translating scientific breakthroughs into safe and effective solutions for patients with rare and common retinal conditions, while striving to lead global innovation in ophthalmic gene therapy.Explore more
Opus Genetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Opus Genetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Opus Genetics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Opus Genetics recently announced quarterly report
Check out if Opus Genetics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Opus Genetics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Opus Genetics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Opus Genetics has new funding data
Product Launch: Get notified when Opus Genetics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Opus Genetics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Opus Genetics
Compare insights from companies similar to Opus Genetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Opus Genetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Opus Genetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Opus Genetics.
Opus Genetics financials insights
Gather financial insights about Opus Genetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$4.5M
2026
Stock/Share Issuance
$159.9M
Opus Genetics Tech Stack
A closer look at the technologies used by Opus Genetics
Most Recent Scoops
Project
Opus Genetics has announced that the September data readout will include best-corrected visual acuity, low luminance visual acuity, microperimetry, contrast sensitivity, OCT volumetric fluid analysis, and ellipsoid zone area quantification, with microperimetry identified as a strong primary endpoint candidate for its low standard deviation.
Medical Research
Project
Opus Genetics has reported that the trial sentinel patient, a 63-year-old woman who had been legally blind since her early thirties, achieved a 12-letter best-corrected visual acuity gain from a baseline.
Medical Research
Project
Opus Genetics is advancing its MERTK gene therapy program using an AAV2 capsid targeting the retinal pigment epithelium, with the clinical trial to be conducted in Abu Dhabi, where MERTK is the third leading cause of genetic blindness in the Middle East.
Medical Research, Pharmaceuticals
Project
Opus Genetics has reported that the sentinel patient in its LCA5 gene therapy program, a 26-year-old with hand motion vision at baseline.
Medical Research
Partnership
Partnership, Pharmaceuticals
Opus Genetics News & Media
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Opus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceOpus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Opus Genetics
Sign Up For FreeTo access detailed company insights
Opus Genetics is a clinical-stage biopharmaceutical company in the biotechnology and ophthalmology industry, focused on developing innovative gene therapies for inherited retinal diseases and other retinal and refractive disorders. Headquartered in the United States, the company conducts research and development in ophthalmic gene therapies and is... Read More
